Comparative results of methods of hair physiotherapy in patients with muscamental disease after remote shock-wave litotreption with the purpose of building the surface of the ureter by sand and small fragments of concrement

Under the conditions of the SBKB SB “OCH No. 1”, the efficacy of using lidocaine-electrophoresis and SMT-therapy after a shock wave-lithotripsy (ESWL) session in patients with urolithiasis was estimated with the aim of arresting the pain syndrome and improving the escape of accumulations of sand and small fragments of stone from the ureter (The “stone path”). All patients (127 people) were divided into 4 groups. Group I patients (31 patients) received an electrophoresis of a 2% solution of lidocaine on the right or left iliac region. In group II (33 people) was carried out by the SMT-therapy on the lumbar and iliac region by the ESWL. In the third group (31 patients), combined treatment was used: electrophoresis of 2% lidocaine and CMT-therapy. In all three groups, physiotherapy was performed against the background of basic treatment (uroantiseptics, non-steroidal anti-inflammatory drugs, drinking regimen). In Group IV (32 patients), patients received only basic therapy. As a result of combined physiotherapy (group III), the severity of dysuric and pain syndrome is reliably reduced.В условиях ГБУЗ СО «СОКБ № 1» была оценена эффективность использования лидокаин-электрофореза и СМТ-терапии после сеанса дистанционной ударно-волновой литотрипсии (ДУВЛ) у больных мочекаменной болезнью (МКБ) с целью купирования болевого синдрома и улучшения отхождения скоплений песка и мелких фрагментов камня из мочеточника («каменная дорожка»). Все больные (127 чел.) были разделены на 4 группы. Пациенты I группы (31 чел.) получали электрофорез 2% раствора лидокаина на правую или левую подвздошную область. Во II группе (33 чел.) проводилась СМТ-терапия на поясничную и подвздошную область со стороны проведенной ДУВЛ. В III группе (31 чел.) было использовано комбинированное лечение: электрофорез 2% раствора лидокаина и СМТ-терапия. Во всех трех группах физиотерапия проводилась на фоне базового лечения (уроантисептики, нестероидные противовоспалительные препараты, питьевой режим). В IV группе (32 чел.) пациенты получали только базовую терапию. В результате комбинированной физиотерапии (III группа) удалось достоверно снизить выраженность дизурического и болевого синдрома

Balneotherapy of patients with urolithiasis after remote shock wave lithotripsy in the second stage of medical rehabilitation

"Stone path" is a condition in which there is accumulation in the ureter of sand and small fragments of stone after a session of remote shock wave lithotripsy (ESWL). The formation of an extended "stone path" (more than 1.5 cm) depends on the internal and transitional type of the pelvis structure, as well as on the density of the calculus. We have studied the possibility of using balneological treatment, including ingestion of mineral water for the purpose of controlled stimulation of diuresis in patients who underwent ESWL, who had a risk of forming a "stone path" in the postoperative period. The study involved 97 patients who underwent clinical rehabilitation in outpatient and sanatorium-resort conditions between 2015 and 2017.«Каменная дорожка» - это состояние, при котором наблюдается скопление в мочеточнике песка и мелких фрагментов камня после сеанса дистанционной ударно-волновой литотрипсии (ДУВЛ). Формирование протяженной «каменной дорожки» (более 1,5см) зависит от внутреннего и переходного типа строения лоханки, а также от плотности конкремента. Нами изучена возможность применения бальнеологического лечения, включающего прием внутрь минеральной воды с целью контролируемого стимулирования диуреза у пациентов, перенесших ДУВЛ, у которых наблюдался риск формирования «каменной дорожки» в послеоперационном периоде. В исследовании приняло участие 97 пациентов, проходивших медицинскую реабилитацию в амбулаторных и санаторно-курортных условиях в период с 2015 по 2017гг

The effect of eurycoma longifolia jack (Tongkat Ali) root extract on salivary s. mutans, lactobacillus and candida albicans isolated from high-risk caries adult patients

Introduction: The roots of E. longifolia jack (E.L.) or Tongkat Ali have been used in traditional medicine as well as supplements and food additives. Many chemical compounds have been detected in extracts of its roots which are believed to be responsible for its medicinal properties. In this study, our objectives were to study the effects of EL root extracts on the growth of Streptococcus Mutans, Lactobacillus and Candida Albicans isolated from saliva of adult patients with high caries risk. Materials and Methods: The ethanolic extract of the root of this plant was tested against saliva isolated Streptococcus Mutans, Lactobacillus and Candida Albicans via disc diffusion assay at a concentration of 200mg/mL. The minimum inhibitory concentration was carried out by the standard broth microdilution method. Cell viability of test microorganisms against different concentration of the extract and inhibition zones were calculated. Results: Disk diffusion assay showed positive zones of inhibition for all test microorganisms with S. mutans, Lactobacillus and C. albicans exhibiting zones of inhibition of 8.3 ± 0.7mm, 12.4 ± 2.4mm and 21.4 ± 2.7mm respectively. For minimum inhibitory concentration, the test microorganisms were tested at concentration of 250mg/ mL, 125mg/mL, 62.5mg/mL, 31.3mg/mL and 0mg/mL. The minimum inhibitory concentration showed that MIC of S. mutans was at 62.5mg/mL, Lactobacillus at 125mg/mL and C. albicans at 31.3mg/mL. Lastly, the cell viability results supported the MIC determined prior. Conclusion: Ethanol-based E. longifolia Jack root extract has an antimicrobial effect on the following microorganisms isolated from the saliva of high-risk caries adult patients: S. mutans, Lactobacillus and C. albicans

The use of pulsed sonar underwater shower-massage after extracorporeal shock wave lithotripsy in patients with urolithiasis in the postoperative period

The objective of this work was to study the dynamics of change in subjective sensations (pain and dysuric syndrome), indicators of urinalysis, ultrasound pictures of the kidneys and upper urinary tract when carrying out physiotherapeutic treatment (sonar underwater shower-massage) and without it. The task is solved in that patients suffering from urolithiasis after ESWL held daily session sonar underwater shower-massage with subsequent assessment of the dynamics of change in subjective sensations (pain and dysuric syndrome), indicators of 0AM, ultrasound pictures of the kidneys and the upper urinary tract for 5,7 and 9 day. Analysis of the obtained data allowed to reveal the improvement of the above parameters in patients after ESWL carried out with further physiotherapy treatment, in comparison with patients without carried out physiotherapeutic treatment.Целью данной работы явилась изучение динамики изменения субъективных ощущений (дизурический и болевой синдром), показателей ОАМ, УЗИ-картины почек и верхних мочевых путей при проведении физиотерапевтического лечения (гидроакустический подводный душ-массаж) и без него. Поставленная задача решается тем, что пациентам, страдающим мочекаменной болезнью после проведенной ДУВЛ выполняется ежедневный сеанс гидроакустического подводного душ-массажа с последующей оценкой динамики изменения субъективных ощущений (дизурический и болевой синдром), показателей ОАМ, УЗИ-картины почек и верхних мочевых путей на 5,7 и 9 сутки. Анализ полученных данных позволил выявить улучшение вышеуказанных показателей у пациентов после проведенного ДУВЛ с последующим физиотерапевтическим лечением, в сравнении с пациентами без проведенного физиотерапевтического лечения

Infected pancreatic necrosis: outcomes and clinical predictors of mortality. A post hoc analysis of the MANCTRA-1 international study

: The identification of high-risk patients in the early stages of infected pancreatic necrosis (IPN) is critical, because it could help the clinicians to adopt more effective management strategies. We conducted a post hoc analysis of the MANCTRA-1 international study to assess the association between clinical risk factors and mortality among adult patients with IPN. Univariable and multivariable logistic regression models were used to identify prognostic factors of mortality. We identified 247 consecutive patients with IPN hospitalised between January 2019 and December 2020. History of uncontrolled arterial hypertension (p = 0.032; 95% CI 1.135-15.882; aOR 4.245), qSOFA (p = 0.005; 95% CI 1.359-5.879; aOR 2.828), renal failure (p = 0.022; 95% CI 1.138-5.442; aOR 2.489), and haemodynamic failure (p = 0.018; 95% CI 1.184-5.978; aOR 2.661), were identified as independent predictors of mortality in IPN patients. Cholangitis (p = 0.003; 95% CI 1.598-9.930; aOR 3.983), abdominal compartment syndrome (p = 0.032; 95% CI 1.090-6.967; aOR 2.735), and gastrointestinal/intra-abdominal bleeding (p = 0.009; 95% CI 1.286-5.712; aOR 2.710) were independently associated with the risk of mortality. Upfront open surgical necrosectomy was strongly associated with the risk of mortality (p < 0.001; 95% CI 1.912-7.442; aOR 3.772), whereas endoscopic drainage of pancreatic necrosis (p = 0.018; 95% CI 0.138-0.834; aOR 0.339) and enteral nutrition (p = 0.003; 95% CI 0.143-0.716; aOR 0.320) were found as protective factors. Organ failure, acute cholangitis, and upfront open surgical necrosectomy were the most significant predictors of mortality. Our study confirmed that, even in a subgroup of particularly ill patients such as those with IPN, upfront open surgery should be avoided as much as possible. Study protocol registered in ClinicalTrials.Gov (I.D. Number NCT04747990)

The global burden of adolescent and young adult cancer in 2019 : a systematic analysis for the Global Burden of Disease Study 2019

Background In estimating the global burden of cancer, adolescents and young adults with cancer are often overlooked, despite being a distinct subgroup with unique epidemiology, clinical care needs, and societal impact. Comprehensive estimates of the global cancer burden in adolescents and young adults (aged 15-39 years) are lacking. To address this gap, we analysed results from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019, with a focus on the outcome of disability-adjusted life-years (DALYs), to inform global cancer control measures in adolescents and young adults. Methods Using the GBD 2019 methodology, international mortality data were collected from vital registration systems, verbal autopsies, and population-based cancer registry inputs modelled with mortality-to-incidence ratios (MIRs). Incidence was computed with mortality estimates and corresponding MIRs. Prevalence estimates were calculated using modelled survival and multiplied by disability weights to obtain years lived with disability (YLDs). Years of life lost (YLLs) were calculated as age-specific cancer deaths multiplied by the standard life expectancy at the age of death. The main outcome was DALYs (the sum of YLLs and YLDs). Estimates were presented globally and by Socio-demographic Index (SDI) quintiles (countries ranked and divided into five equal SDI groups), and all estimates were presented with corresponding 95% uncertainty intervals (UIs). For this analysis, we used the age range of 15-39 years to define adolescents and young adults. Findings There were 1.19 million (95% UI 1.11-1.28) incident cancer cases and 396 000 (370 000-425 000) deaths due to cancer among people aged 15-39 years worldwide in 2019. The highest age-standardised incidence rates occurred in high SDI (59.6 [54.5-65.7] per 100 000 person-years) and high-middle SDI countries (53.2 [48.8-57.9] per 100 000 person-years), while the highest age-standardised mortality rates were in low-middle SDI (14.2 [12.9-15.6] per 100 000 person-years) and middle SDI (13.6 [12.6-14.8] per 100 000 person-years) countries. In 2019, adolescent and young adult cancers contributed 23.5 million (21.9-25.2) DALYs to the global burden of disease, of which 2.7% (1.9-3.6) came from YLDs and 97.3% (96.4-98.1) from YLLs. Cancer was the fourth leading cause of death and tenth leading cause of DALYs in adolescents and young adults globally. Interpretation Adolescent and young adult cancers contributed substantially to the overall adolescent and young adult disease burden globally in 2019. These results provide new insights into the distribution and magnitude of the adolescent and young adult cancer burden around the world. With notable differences observed across SDI settings, these estimates can inform global and country-level cancer control efforts. Copyright (C) 2021 The Author(s). Published by Elsevier Ltd.Peer reviewe

Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019: A Systematic Analysis for the Global Burden of Disease Study 2019.

The Global Burden of Diseases, Injuries, and Risk Factors Study 2019 (GBD 2019) provided systematic estimates of incidence, morbidity, and mortality to inform local and international efforts toward reducing cancer burden. To estimate cancer burden and trends globally for 204 countries and territories and by Sociodemographic Index (SDI) quintiles from 2010 to 2019. The GBD 2019 estimation methods were used to describe cancer incidence, mortality, years lived with disability, years of life lost, and disability-adjusted life years (DALYs) in 2019 and over the past decade. Estimates are also provided by quintiles of the SDI, a composite measure of educational attainment, income per capita, and total fertility rate for those younger than 25 years. Estimates include 95% uncertainty intervals (UIs). In 2019, there were an estimated 23.6 million (95% UI, 22.2-24.9 million) new cancer cases (17.2 million when excluding nonmelanoma skin cancer) and 10.0 million (95% UI, 9.36-10.6 million) cancer deaths globally, with an estimated 250 million (235-264 million) DALYs due to cancer. Since 2010, these represented a 26.3% (95% UI, 20.3%-32.3%) increase in new cases, a 20.9% (95% UI, 14.2%-27.6%) increase in deaths, and a 16.0% (95% UI, 9.3%-22.8%) increase in DALYs. Among 22 groups of diseases and injuries in the GBD 2019 study, cancer was second only to cardiovascular diseases for the number of deaths, years of life lost, and DALYs globally in 2019. Cancer burden differed across SDI quintiles. The proportion of years lived with disability that contributed to DALYs increased with SDI, ranging from 1.4% (1.1%-1.8%) in the low SDI quintile to 5.7% (4.2%-7.1%) in the high SDI quintile. While the high SDI quintile had the highest number of new cases in 2019, the middle SDI quintile had the highest number of cancer deaths and DALYs. From 2010 to 2019, the largest percentage increase in the numbers of cases and deaths occurred in the low and low-middle SDI quintiles. The results of this systematic analysis suggest that the global burden of cancer is substantial and growing, with burden differing by SDI. These results provide comprehensive and comparable estimates that can potentially inform efforts toward equitable cancer control around the world.Funding/Support: The Institute for Health Metrics and Evaluation received funding from the Bill & Melinda Gates Foundation and the American Lebanese Syrian Associated Charities. Dr Aljunid acknowledges the Department of Health Policy and Management of Kuwait University and the International Centre for Casemix and Clinical Coding, National University of Malaysia for the approval and support to participate in this research project. Dr Bhaskar acknowledges institutional support from the NSW Ministry of Health and NSW Health Pathology. Dr Bärnighausen was supported by the Alexander von Humboldt Foundation through the Alexander von Humboldt Professor award, which is funded by the German Federal Ministry of Education and Research. Dr Braithwaite acknowledges funding from the National Institutes of Health/ National Cancer Institute. Dr Conde acknowledges financial support from the European Research Council ERC Starting Grant agreement No 848325. Dr Costa acknowledges her grant (SFRH/BHD/110001/2015), received by Portuguese national funds through Fundação para a Ciência e Tecnologia, IP under the Norma Transitória grant DL57/2016/CP1334/CT0006. Dr Ghith acknowledges support from a grant from Novo Nordisk Foundation (NNF16OC0021856). Dr Glasbey is supported by a National Institute of Health Research Doctoral Research Fellowship. Dr Vivek Kumar Gupta acknowledges funding support from National Health and Medical Research Council Australia. Dr Haque thanks Jazan University, Saudi Arabia for providing access to the Saudi Digital Library for this research study. Drs Herteliu, Pana, and Ausloos are partially supported by a grant of the Romanian National Authority for Scientific Research and Innovation, CNDS-UEFISCDI, project number PN-III-P4-ID-PCCF-2016-0084. Dr Hugo received support from the Higher Education Improvement Coordination of the Brazilian Ministry of Education for a sabbatical period at the Institute for Health Metrics and Evaluation, between September 2019 and August 2020. Dr Sheikh Mohammed Shariful Islam acknowledges funding by a National Heart Foundation of Australia Fellowship and National Health and Medical Research Council Emerging Leadership Fellowship. Dr Jakovljevic acknowledges support through grant OI 175014 of the Ministry of Education Science and Technological Development of the Republic of Serbia. Dr Katikireddi acknowledges funding from a NHS Research Scotland Senior Clinical Fellowship (SCAF/15/02), the Medical Research Council (MC_UU_00022/2), and the Scottish Government Chief Scientist Office (SPHSU17). Dr Md Nuruzzaman Khan acknowledges the support of Jatiya Kabi Kazi Nazrul Islam University, Bangladesh. Dr Yun Jin Kim was supported by the Research Management Centre, Xiamen University Malaysia (XMUMRF/2020-C6/ITCM/0004). Dr Koulmane Laxminarayana acknowledges institutional support from Manipal Academy of Higher Education. Dr Landires is a member of the Sistema Nacional de Investigación, which is supported by Panama’s Secretaría Nacional de Ciencia, Tecnología e Innovación. Dr Loureiro was supported by national funds through Fundação para a Ciência e Tecnologia under the Scientific Employment Stimulus–Institutional Call (CEECINST/00049/2018). Dr Molokhia is supported by the National Institute for Health Research Biomedical Research Center at Guy’s and St Thomas’ National Health Service Foundation Trust and King’s College London. Dr Moosavi appreciates NIGEB's support. Dr Pati acknowledges support from the SIAN Institute, Association for Biodiversity Conservation & Research. Dr Rakovac acknowledges a grant from the government of the Russian Federation in the context of World Health Organization Noncommunicable Diseases Office. Dr Samy was supported by a fellowship from the Egyptian Fulbright Mission Program. Dr Sheikh acknowledges support from Health Data Research UK. Drs Adithi Shetty and Unnikrishnan acknowledge support given by Kasturba Medical College, Mangalore, Manipal Academy of Higher Education. Dr Pavanchand H. Shetty acknowledges Manipal Academy of Higher Education for their research support. Dr Diego Augusto Santos Silva was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil Finance Code 001 and is supported in part by CNPq (302028/2018-8). Dr Zhu acknowledges the Cancer Prevention and Research Institute of Texas grant RP210042

Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019: A Systematic Analysis for the Global Burden of Disease Study 2019

Importance: The Global Burden of Diseases, Injuries, and Risk Factors Study 2019 (GBD 2019) provided systematic estimates of incidence, morbidity, and mortality to inform local and international efforts toward reducing cancer burden. Objective: To estimate cancer burden and trends globally for 204 countries and territories and by Sociodemographic Index (SDI) quintiles from 2010 to 2019. Evidence Review: The GBD 2019 estimation methods were used to describe cancer incidence, mortality, years lived with disability, years of life lost, and disability-adjusted life years (DALYs) in 2019 and over the past decade. Estimates are also provided by quintiles of the SDI, a composite measure of educational attainment, income per capita, and total fertility rate for those younger than 25 years. Estimates include 95% uncertainty intervals (UIs). Findings: In 2019, there were an estimated 23.6 million (95% UI, 22.2-24.9 million) new cancer cases (17.2 million when excluding nonmelanoma skin cancer) and 10.0 million (95% UI, 9.36-10.6 million) cancer deaths globally, with an estimated 250 million (235-264 million) DALYs due to cancer. Since 2010, these represented a 26.3% (95% UI, 20.3%-32.3%) increase in new cases, a 20.9% (95% UI, 14.2%-27.6%) increase in deaths, and a 16.0% (95% UI, 9.3%-22.8%) increase in DALYs. Among 22 groups of diseases and injuries in the GBD 2019 study, cancer was second only to cardiovascular diseases for the number of deaths, years of life lost, and DALYs globally in 2019. Cancer burden differed across SDI quintiles. The proportion of years lived with disability that contributed to DALYs increased with SDI, ranging from 1.4% (1.1%-1.8%) in the low SDI quintile to 5.7% (4.2%-7.1%) in the high SDI quintile. While the high SDI quintile had the highest number of new cases in 2019, the middle SDI quintile had the highest number of cancer deaths and DALYs. From 2010 to 2019, the largest percentage increase in the numbers of cases and deaths occurred in the low and low-middle SDI quintiles. Conclusions and Relevance: The results of this systematic analysis suggest that the global burden of cancer is substantial and growing, with burden differing by SDI. These results provide comprehensive and comparable estimates that can potentially inform efforts toward equitable cancer control around the world

Timing of Cholecystectomy After Moderate and Severe Acute Biliary Pancreatitis

IMPORTANCE Considering the lack of equipoise regarding the timing of cholecystectomy in patients with moderately severe and severe acute biliary pancreatitis (ABP), it is critical to assess this issue.OBJECTIVE To assess the outcomes of early cholecystectomy (EC) in patients with moderately severe and severe ABP.DESIGN, SETTINGS, AND PARTICIPANTS This cohort study retrospectively analyzed real-life data from the MANCTRA-1 (Compliance With Evidence-Based Clinical Guidelines in the Management of Acute Biliary Pancreatitis) data set, assessing 5304 consecutive patients hospitalized between January 1, 2019, and December 31, 2020, for ABP from 42 countries. A total of 3696 patients who were hospitalized for ABP and underwent cholecystectomy were included in the analysis; of these, 1202 underwent EC, defined as a cholecystectomy performed within 14 days of admission. Univariable and multivariable logistic regression models were used to identify prognostic factors of mortality and morbidity. Data analysis was performed from January to February 2023.MAIN OUTCOMES Mortality and morbidity after EC.RESULTS Of the 3696 patients (mean [SD] age, 58.5 [17.8] years; 1907 [51.5%] female) included in the analysis, 1202 (32.5%) underwent EC and 2494 (67.5%) underwent delayed cholecystectomy (DC). Overall, EC presented an increased risk of postoperative mortality (1.4% vs 0.1%, P <.001) and morbidity (7.7% vs 3.7%, P < .001) compared with DC. On the multivariable analysis, moderately severe and severe ABP were associated with increased mortality (odds ratio [OR], 361.46; 95% CI, 2.28-57 212.31; P = .02) and morbidity (OR, 2.64; 95% CI, 1.35-5.19; P = .005). In patients with moderately severe and severe ABP (n = 108), EC was associated with an increased risk of mortality (16 [15.6%] vs 0 [0%], P < .001), morbidity (30 [30.3%] vs 57 [5.5%], P < .001), bile leakage (2 [2.4%] vs 4 [0.4%], P = .02), and infections (12 [14.6%] vs 4 [0.4%], P < .001) compared with patients with mild ABP who underwent EC. In patients with moderately severe and severe ABP (n = 108), EC was associated with higher mortality (16 [15.6%] vs 2 [1.2%], P < .001), morbidity (30 [30.3%] vs 17 [10.3%], P < .001), and infections (12 [14.6%] vs 2 [1.3%], P < .001) compared with patients with moderately severe and severe ABP who underwent DC. On the multivariable analysis, the patient's age (OR, 1.12; 95% CI, 1.02-1.36; P = .03) and American Society of Anesthesiologists score (OR, 5.91; 95% CI, 1.06-32.78; P = .04) were associated with mortality; severe complications of ABP were associated with increased mortality (OR, 50.04; 95% CI, 2.37-1058.01; P = .01) and morbidity (OR, 33.64; 95% CI, 3.19-354.73; P = .003).CONCLUSIONS AND RELEVANCE This cohort study's findings suggest that EC should be considered carefully in patients with moderately severe and severe ABP, as it was associated with increased postoperative mortality and morbidity. However, older and more fragile patients manifesting severe complications related to ABP should most likely not be considered for EC